Latest 10-Q quarterly reports

Magnolia Bancorp, Inc. reported a net loss of $69,000 for the first quarter of 2026, a decrease from the prior year's loss, driven by increased noninterest expenses.

BETA Technologies reports a 6% increase in Q1 2026 revenue driven by service growth, while research and development expenses significantly rise to support electric aircraft development.

Vishay Precision Group announced its first quarter 2026 financial results, with net revenues increasing 17.6% year-over-year to $84.4 million, driven by strong performance across all reporting segments.

Sharing Economy International Inc. reports a net loss of $97,330 for Q1 2026, with no revenues and increased operating expenses.

Evolution Global Acquisition Corp reports net income of $1.95 million for Q1 2026, primarily from trust account interest, while continuing its search for a business combination.

Advanced Oxygen Technologies reports modest revenue growth and net income for the nine months ending March 31, 2026, with primary operations in Danish real estate leasing.

Connect Biopharma Holdings Limited reported a net loss of $19.4 million for Q1 2026, with a significant increase in R&D expenses, offset by proceeds from a private placement that bolstered cash reserves.

United-Guardian reports a 16% increase in Q1 2026 net sales, driven by strong performance in pharmaceutical products and cosmetic ingredients, alongside a significant settlement income.

Ton Strategy Company's Q1 2026 report shows significant revenue growth driven by its TON segment, alongside a substantial unrealized loss on digital assets.

Aureus Greenway Holdings Inc. reported an 11% increase in total revenue for the first quarter of 2026, driven by growth across all segments, but experienced a net loss due to significantly higher operating expenses.

Energy Focus, Inc. reported a 54% increase in net sales for Q1 2026 compared to the prior year, driven by its Military Maritime Market (MMM) and commercial product lines, though the company continues to incur net losses.

Imunon, Inc. filed its Q1 2026 Form 10-Q, detailing a net loss of $4.2 million and continued progress in its Phase 3 OVATION 3 ovarian cancer trial.

SPAR Group reported a 10.3% decrease in net revenues for the first quarter of 2026, primarily driven by a slowdown in its remodel business.

Giftify, Inc. reported a 4.1% decrease in net sales for Q1 2026, but a significant 18.5% increase in gross profit, driven by a shift towards higher-margin agent transactions.

SideChannel, Inc. reported its Q2 2026 results, showing a decrease in revenue and a continued net loss, while also highlighting substantial doubt about its ability to continue as a going concern.

Leatt Corporation reported a strong first quarter for 2026, with revenues increasing by 27% year-over-year, driven by significant growth in helmet and body armor sales.

NeuroOne Medical Technologies reported increased product revenue in Q1 2026, though net loss widened due to license revenue recognition in the prior year.

ProMIS Neurosciences Inc. reported its first quarter 2026 financial results, highlighting significant progress in its Alzheimer's drug candidate PMN310 and a substantial increase in cash reserves following a successful private placement.

Adagio Medical Holdings, Inc. reported reduced net losses for the first quarter of 2026 compared to the prior year, driven by decreased operating expenses, though the company continues to face substantial going concern risks.

Mereo BioPharma reports a narrower net loss for Q1 2026 compared to the prior year, driven by lower administrative expenses and foreign currency gains, alongside increased R&D spending primarily on setrusumab.

OptimumBank Holdings, Inc. reports a strong first quarter for 2026 with significant growth in net income, driven by increased net interest income and noninterest income, alongside strategic expansion initiatives.

PMV Pharmaceuticals reports a net loss of $18.0 million for Q1 2026, with operating expenses decreasing but interest income also declining, while maintaining sufficient cash for the next 12 months.

CVRx, Inc. announced its first quarter 2026 financial results, showcasing a 20% increase in revenue driven by strong U.S. sales, while also reporting a slight reduction in net loss compared to the prior year period.

Coya Therapeutics reports a decrease in R&D expenses and an increase in G&A for Q1 2026, with cash reserves projected to last into the second half of 2027.

Xilio Therapeutics, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing increased collaboration revenue, higher R&D spending, and a strengthened cash position.

SAB Biotherapeutics details significant R&D investment and progress in its lead Type 1 Diabetes therapy, SAB-142, alongside a substantial capital raise.

Sagimet Biosciences reports a significant decrease in R&D expenses for Q1 2026, improved cash flow from investing activities, and sufficient liquidity for the next 12 months following a substantial capital raise.

Longduoduo Company Limited reported a significant decrease in revenue for the third quarter of fiscal year 2026, driven by economic headwinds and cautious consumer spending.

Achieve Life Sciences reported its first quarter 2026 financial results, highlighting a net loss of $10.2 million and a significant capital raise of $180 million, while also anticipating a delay in FDA approval for cytisinicline.

Prelude Therapeutics Inc. reported its first-quarter 2026 financial results, highlighting progress in its oncology pipeline and a significant cash position following a recent offering.